Factory Supply Baloxavir Marboxil Powder CAS 1985606-14-1 Baloxavir Marboxil
2 Inquiries
1985606-14-1
Pharmaceutical Grade
0%
Foil Bag
2022-12-31
Minoxidil,Paracetamol,Diclofenac sodium,fenbendazole,Ivermectin
-
Product Description
-
Seller Information
-
Inquiry History
-
Description
In February 2018, baloxavirmarboxil (trade name: xofluza), a new anti influenza drug developed by Shionogi of Japan and jointly studied with Roche of Switzerland, was accelerated in Japan and approved for listing. Baloxavir axetil is an innovative cap dependent endonuclease inhibitor. It is also one of the few new drugs in the world that can inhibit the proliferation of influenza virus.
Basic Info-
Product Name:
[[(12aR)-12-[(11S)-7,8-Difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-3,4,6,8,12,12a-hexahydro-6,8-dioxo-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl]oxy]methyl methyl carbonate
Other Name:Carbonic acid,[[(12aR)-12-[(11S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-3,4,6,8,12,12a-hexahydro-6,8-dioxo-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl]oxy]methyl methyl ester;[[(12aR)-12-[(11S)-7,8-Difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-3,4,6,8,12,12a-hexahydro-6,8-dioxo-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl]oxy]methyl methyl carbonate;Baloxavir marboxil;S 033188;({(12aR)-12-[(11S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl}oxy)methyl methyl carbonate;Xofluza;RG-6152;RG6152;RG 6152
CAS No.:1985606-14-1
Molecular Formula:C27H23F2N3O7S
InChIKeys:InChIKey=RZVPBGBYGMDSBG-GGAORHGYSA-N
Molecular Weight:571.6
Exact Mass:571.55
UNII:505CXM6OHG
NCI Thesaurus Code:C166177
ATC Code:J - Antiinfectives for systemic use
Categories:
Characteristics-
XLogP3:
2.24
Water Solubility:Soluble in water
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Minoxidil,Paracetamol,Diclofenac sodium,fenbendazole,Ivermectin
-
Location:
I-City unit 3, South of Tangyan Road, Hi-Tech Industrial Zone, Xi'an City, Shaanxi Province, China
-
Payment Terms:
TT against copy of documents,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
51-100
-
Year of Establishment:
2015
-
Certifications:
HACCP,Halal,GMP,ISO
"> -
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted
United States
Baloxavir marboxil Pharmaceutical Raw Powder CAS
100 G Aug 21, 2025
Egypt
Baloxavir Marboxil
3 KG Jun 5, 2026 Post an enquiry for this product